

2nd World Congress on RARE DISEASES

June 30, 2021 | Webinar

Procalcitonin: A Tool to Assist with Risk Assessment and Likelihood of Bacterial Co-infection in COVID-19**Diane M. Borkowski***Thermo Scientific, Middletown, VA 22645*

COVID-19 has dramatically impacted the modern healthcare system across the continuum of care. This session will explore the role of procalcitonin (PCT) in SARS-CoV-2 to aid in the differential diagnosis of bacterial coinfection, severity of bacterial burden and disease evolution to determine the need for antimicrobial therapy. Antibiotic stewardship during the COVID-19 pandemic is a critical part of the comprehensive strategy to improve patient outcomes and reduce long-term adverse effects secondary to rising antibiotic resistance.

Biography

Senior Medical Science Liaison for Thermo Fisher Scientific with a Bachelor of Science in Health Care Management and Nursing Diploma graduate with thirty+ years of professional experience in critical care. My clinical focus is to provide evidence-based information on biomarkers of infection, including Procalcitonin (PCT) along with resources which include: updated peer-reviewed publication lists; Grand Round / CME support, Clinical Professional Organizations, Critical Care, Antibiotic Stewardship & Sepsis Committee presentations, develop clinical education tools and protocol / order set consultation.

My clinical experience includes ICU/CCU, Interventional Cardiology / Radiology and ED in various positions: staff, management and education. I have published on thrombolytics, provided educational programs for CE credit and served on a nursing journal editorial board.

diane.borkowski@thermofisher.com